Jerome Schartman, MD
Retina Specialist · Beachwood, OHNPI 1912113069
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (44.0%), ownership interests and food and beverage — rather than concentrated in one kind of arrangement. US Retina LLC accounts for 82.4% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2022 at $17,348 and has fallen 93.4% since, to $1,137 in 2025.
Across 176 payments — averaging $171.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$25K
- Regeneron Healthcare Solutions, Inc.$1K
- AbbVie$860
- Dutch Ophthalmic, USA$515
- Alimera Sciences, Inc.$478
- Genentech USA, Inc.$411
- plus $2K from 16 others
Across 2 payments — averaging $9500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eyepoint US, Inc.$10K
- Alimera Sciences, Inc.$10K
What the payments were for
- Food & beverage$5,30818%
- Education$140%
- Ownership interest$11,59438%
- Other$13,30744%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 7 | $24,901 |
| Regeneron Healthcare Solutions, Inc. | 61 | $1,455 |
| AbbVie(2 entities) | 24 | $860 |
| Dutch Ophthalmic, USA | 4 | $515 |
| Alimera Sciences, Inc. | 15 | $478 |
| Genentech USA, Inc. | 8 | $411 |
| Apellis Pharmaceuticals, Inc. | 12 | $379 |
| Alcon | 3 | $184 |
| Eyepoint US, Inc. | 10 | $182 |
| Astellas Pharma US Inc | 7 | $180 |
| Coherus Oncology, Inc. | 3 | $174 |
| Bausch & Lomb Americas Inc. | 3 | $141 |
| ANI Pharmaceuticals, Inc. | 5 | $103 |
| Rayner Intraocular Lenses Limited | 3 | $45 |
| Harrow Eye, LLC | 2 | $45 |
| Biogen | 2 | $44 |
| Novartis | 2 | $40 |
| Carl Zeiss Meditec USA, Inc. | 1 | $30 |
| Neurotech Pharmaceuticals, Inc. | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $12 |
| Sun Pharmaceutical Industries Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$416
- VABYSMO$280
- Iluvien$253
- EVA, combined machine$252
- TISSUEBLUE$252
- OZURDEX$240
- EVA Ophthalmic Surgical System$162
- Hydrus Microstent$149
- SUSVIMO$143
- EYLEA HD$139
- Cimerli$135
- XIPERE$100
How this compares
$30,223 in reported general payments places this provider in the 80th percentile of 69 retina specialist providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 537 | $13,443 |
| Alphagan PBrimonidine Tartrate | 13 | $4,570 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 40 | $3,863 |
| Brimonidine Tartrate | 75 | $3,619 |
| LumiganBimatoprost | 11 | $3,235 |
| Bromfenac Sodium | 15 | $2,335 |
| Latanoprost | 231 | $2,191 |
| Ketorolac Tromethamine | 171 | $2,170 |
| Difluprednate | 24 | $1,750 |
| Ofloxacin | 156 | $1,479 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 63 | $747 |
| ValacyclovirValacyclovir Hcl | 16 | $573 |
| Timolol Maleate | 97 | $504 |
| Acetazolamide | 15 | $402 |
| ErythromycinErythromycin Base | 31 | $301 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieAlphagan P, Lumigan | $860 | $7,80424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 69 retina specialist providers in Ohio.
Other retina specialist in Beachwood
- Joseph ConeyBeachwood$980K
- David MillerBeachwood$299K
- Michael NovakBeachwood$71K
- Scott PendergastBeachwood$66K
- Llewelyn RaoBeachwood$58K
- Sean PlattBeachwood$23K
- Lediana GoduniBeachwood$9K
- Shawn LewisBeachwood$7K
- David ShiehBeachwood$3K
- Hernando ZegarraBeachwood$478
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.